Third US patent on Israeli Teva's MS drug Copaxone invalidated

NEW YORK- US patent officials on Thursday invalidated a third patent covering Israel's Teva Pharmaceutical Industries' $4 billion multiple sclerosis treatment Copaxone, after canceling two other patents on the drug last week.
The ruling came in a challenge at the US Patent and Trademark Office by Mylan NV, which is trying to bring out a generic version of the 40-milligram injectable drug, taken three times a week. According to the US Food and Drug Administration, Copaxone is protected by five patents in total.
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy